Purpose: Smith-Magenis syndrome (SMS) is a complex disorder that includes mental retardation, craniofacial and skeletal anomalies, and behavioral abnormalities. We report the molecular and ...

In the assessment of 12-month price targets, analysts unveil insights for Vanda Pharma, presenting an average target of $18.4 ...

Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for ...

Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 Full year 2024 total ...

Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...

Vanda's MAA for HETLIOZ and HETLIOZ LQ for Smith-Magenis Syndrome is now pending with the European Medicines Agency. In addition, Vanda is continuing to pursue the approval of HETLIOZ in sleep ...

Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for ...

Ted was born with Smith-Magenis Syndrome, a rare genetic condition that significantly affects his ability to communicate. A paper-based communication book has already made a positive difference ...

BMMT provides a form of expression and an avenue to develop areas that traditional therapies or learning may not provide for either individuals facing: Autism,Smith-Magenis Syndrome Sensory ...